U.S. Medical Equipment Stock News

XTransfer, a leading B2B cross-border trade payment platform, has been named to CNBC's 2026 list of the World's Top Fintech Companies in the Payments Segment, highlighting its growing impact in the digital payments landscape. This recognition underscores the company's commitment to providing secure and efficient cross-border payment solutions for SMEs, thereby addressing the complexities of international financial operations. XTransfer's inclusion in this prestigious list, compiled with...

BJ's Restaurants (BJRI) stock was in focus after Q2 2026 results showed sales of $388.89 million and adjusted EPS of $0.94, with management highlighting commodity cost pressures and expectations for margin improvement ahead. See our latest analysis for BJ's Restaurants. Despite a sharp 8.96% decline in the latest 1 day share price return, BJ's Restaurants stock has shown strong recent momentum, with a 30 day share price return of 11.40% and a 1 year total shareholder return of 97.86%,...

The latest Federal Reserve meeting kept interest rates on hold but still triggered the Dow’s worst single-session drop in over a year and exposed rare internal division at the FOMC. With inflation at 4.2% and pressure building on long-term Treasury yields, many investors are reassessing how much risk they want to carry in rate sensitive areas of the market. This article looks at three dividend paying stocks from our Defensive Dividend Stocks screener that appear closely tied to these cross...

Renewed interest in MKS (MKSI) as a supplier to AI focused semiconductor equipment and complex circuit boards has pushed the stock sharply higher, with investors debating whether the recent move reflects perceived undervaluation. See our latest analysis for MKS. Recent trading in MKS reflects a mixed picture, with the share price down 27.64% over the past 30 days but still showing strong momentum over longer periods. This includes a 76.68% year to date share price return and a 222.42% total...

Newmark Group, Inc. reported its second-quarter 2026 results, showing higher sales and revenue year over year, while net income and earnings per share from continuing operations were broadly stable, alongside continued share repurchases and a reaffirmed quarterly dividend of US$0.0600 per share. An interesting takeaway is that, despite only modest quarterly net income movement, Newmark has now repurchased over half of its shares originally authorized under the long-running buyback program,...

Recent performance snapshot for Navigator Holdings Navigator Holdings (NYSE:NVGS) has drawn investor attention after a period of strong share price performance, with the stock up 20.0% over the past month and 2.1% over the past 3 months. The company, which owns and operates 57 liquefied gas carriers, last closed at US$22.35, giving it a market value of about US$1.37b based on the latest available data. See our latest analysis for Navigator Holdings. The recent 20.0% 1 month share price return...

Euronet Worldwide earnings and buyback activity in focus Euronet Worldwide (EEFT) reported second quarter 2026 results that combined higher sales with lower profitability, while also updating investors on progress under its multi year share repurchase program. Sales for the quarter reached US$1,108.4 million compared with US$1,074.3 million a year earlier. Net income was US$77.4 million versus US$97.6 million, with diluted earnings per share from continuing operations at US$1.71 compared with...

The latest merger speculation swirling around AstraZeneca and Bristol Myers Squibb has pushed large cap pharma stocks back into the spotlight. Sharp price moves, including AstraZeneca’s intraday fall of up to 7% and a 6% premarket jump for Bristol Myers, show how quickly sentiment can shift when potential mega deals hit the headlines. For investors, this kind of disruption can surface both opportunities and risks. This article looks at 3 stocks from a Healthcare screener that are exposed to...

Antero Midstream Corporation recently reported its second-quarter 2026 results, with revenue rising to US$327.24 million while net income eased to US$113.52 million, alongside record adjusted EBITDA and gathering volumes above 4.1 Bcf per day. The company also received over US$370 million in damages and interest, lowering pro forma leverage to 2.8 times and supporting major pipeline expansion plans, including the East Side Express project. We’ll now examine how the damages-driven leverage...

Regeneron Pharmaceuticals (REGN) is back in focus after reporting second quarter 2026 results that showed revenue of US$4.29b, alongside a quarterly dividend declaration and a new radiopharmaceuticals collaboration with Telix Pharmaceuticals. See our latest analysis for Regeneron Pharmaceuticals. At a share price of US$762.63, Regeneron Pharmaceuticals has seen a 30 day share price return of 22.08% and a 1 year total shareholder return of 37.21%. This points to building momentum following...

Autohome (NYSE:ATHM) has announced a new share repurchase program of up to US$400 million. The program has been authorized by its Board and is set to run for 12 months, funded entirely from existing cash reserves. See our latest analysis for Autohome. The buyback news lands after a strong short term share price run for Autohome, with a 7 day share price return of 10.0% and a 30 day return of 21.63% helping to lift the 90 day share price return to 24.84%. However, the 1 year total shareholder...

Cullinan Therapeutics reported that it previously received positive feedback from the U.S. FDA following an End-of-Phase 1 meeting for CLN-049, clearing the way for a potentially registrational Phase 2 trial in relapsed/refractory acute myeloid leukemia and additional combination studies in previously untreated patients. The FDA’s alignment on a seamless Phase 2 design and CLN-049’s Fast Track and Orphan Drug designations together underscore the program’s regulatory momentum in a...

The United States market remained flat over the last week but has shown an impressive 18% rise over the past 12 months, with earnings forecasted to grow by 16% annually. In this context, identifying stocks that are potentially undervalued can be crucial for investors seeking opportunities in a dynamic market environment.

In the last week, the United States market has remained flat, yet it has risen by 18% over the past year with anticipated earnings growth of 16% per annum in the coming years. In this environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervaluation.

Palomino Laboratories has completed its acquisition of Vega Links, positioning itself as a key player in the next-generation AI interconnect field. This strategic move significantly expands Palomino's addressable market to over $60 billion and accelerates its capabilities in AI infrastructure. With the integration of Vega Links’ expertise in high-speed AI and memory connectivity, Palomino aims to enhance AI interconnect technologies that improve bandwidth, latency, and power efficiency...

The United States market remained flat over the last week but has seen an 18% increase over the past year, with earnings forecasted to grow by 16% annually. In such a landscape, growth companies with high insider ownership can be appealing as they often indicate strong confidence from those closest to the business and potential for robust performance.

The market remained flat over the last week, but over the past 12 months, it has risen 18%, with earnings forecast to grow by 16% annually. Investing in penny stocks—though a somewhat outdated term—still highlights opportunities in smaller or newer companies that can offer great value. By focusing on those with robust financials and a clear growth trajectory, investors can find promising opportunities among these lesser-known stocks.

The United States market has experienced a flat week but has seen an impressive 18% rise over the past year, with earnings projected to grow by 16% annually. In this environment, identifying stocks with strong fundamentals and growth potential can be key to uncovering promising opportunities.

The United States market remained flat over the last week but has seen an impressive 18% rise over the past year, with earnings projected to grow by 16% annually. In this context, dividend stocks can be a valuable addition to portfolios, offering potential income and stability amidst fluctuating market conditions.

XBP Global Holdings, Inc. ( NASDAQ:XBP ) is possibly approaching a major achievement in its business, so we would like...

Scorpio Tankers (STNG) is back on investor radar after reporting record Q2 2026 earnings, with net income of US$387.54 million and a quarterly dividend of US$0.45 per share reaffirmed, alongside balance sheet refinancing moves. See our latest analysis for Scorpio Tankers. Scorpio Tankers' record Q2 has arrived after a strong run in the stock, with the share price at US$77.86 and a year to date share price return of 56.69%, while the 1 year total shareholder return of 70.11% reflects sizeable...

Cintas Corporation previously announced that its Board of Directors approved a higher quarterly cash dividend of US$0.52 per share, payable on September 15, 2026, to shareholders of record as of August 14, 2026. This dividend increase underscores management’s confidence in Cintas’ cash generation and reinforces its pattern of returning capital to shareholders through regular income. We’ll now examine how this higher quarterly dividend shapes Cintas’ investment narrative, particularly its...

In late July 2026, Amneal Pharmaceuticals reported past second-quarter results showing sales of US$796.2 million and net income of US$57.66 million, alongside higher earnings per share versus a year earlier. Alongside these stronger results, the company raised its 2026 net revenue guidance to a range of US$3.10 billion to US$3.20 billion, signaling increased confidence in its operating outlook. Next, we’ll examine how Amneal’s raised full-year revenue guidance reshapes the earlier investment...

Gorman-Rupp (GRC) is back on investors screens after its July 24 earnings release, which showed higher second quarter sales and net income compared with a year earlier. That updated snapshot is now driving fresh attention. See our latest analysis for Gorman-Rupp. At a share price of $81.19, Gorman-Rupp has had a 90-day share price return of 6.62%. Its year-to-date share price return of 68.65% and 1-year total shareholder return of 101.54% indicate strong momentum over both shorter and longer...